Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT2 melatonin receptor selective ligands

被引:97
作者
Wallez, V
Durieux-Poissonnier, S
Chavatte, P
Boutin, JA
Audinot, V
Nicolas, JP
Bennejean, C
Delagrange, P
Renard, P
Lesieur, D
机构
[1] Inst Chim Pharmaceut Albert Lespagnol, F-59006 Lille, France
[2] Inst Rech Servier, Div Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France
[3] Inst Rech Int Servier, F-92415 Courbevoie, France
关键词
D O I
10.1021/jm0005252
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of N-(2-phenylbenzofuran-3-yl) ethyl amide and N-(2-arylalkylbenzofuran-3-yl) ethyl amide derivatives were synthesized and evaluated as melatonin receptor ligands. The affinity of each compound for the two MT1 and MT2 melatonin receptor subtypes was determined by binding studies using 2-[I-125] iodomelatonin on human embryonic kidney cell line HEK293 membrane homogenates. The intrinsic activity of the most interesting compounds was evaluated on the [S-35] GTPgammaS binding assay. Introduction of a 2-phenyl substituent in the C-2 benzofuran position leads to an agonist compound, 10q, which binds more strongly than melatonin itself to both MT1 and MT2 subtypes. On the other hand, a 2-benzyl group in the same position allows MT2 antagonist selective ligands to be obtained. The MT2 selectivity and antagonist potency can be modulated with suitable modifications on the N-acyl and benzyl substituents, and the most selective compounds 10c and 19 show affinity ratios of 123 and 192, respectively, and bind to the MT2 subtype similarly to melatonin itself (0.1 nM). Nevertheless, 10c acts as an MT1 and MT2 antagonist, whereas 19 is a partial agonist.
引用
收藏
页码:2788 / 2800
页数:13
相关论文
共 36 条
[1]   Melatonin receptor subtype expression in human cerebellum [J].
Al-Ghoul, WM ;
Herman, MD ;
Dubocovich, ML .
NEUROREPORT, 1998, 9 (18) :4063-4068
[2]   Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor [J].
Audinot, V ;
Beauverger, P ;
Lahaye, C ;
Suply, T ;
Rodriguez, M ;
Ouvry, C ;
Lamamy, V ;
Imbert, J ;
Rique, H ;
Nahon, JL ;
Galizzi, JP ;
Canet, E ;
Levens, N ;
Fauchère, JL ;
Boutin, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) :13554-13562
[3]  
BUZAS A, 1977, SYNTHESIS-STUTTGART, P129
[4]  
CHATTERJEA NJ, 1963, J INDIAN CHEM SOC, V40, P203
[5]   General synthesis of α-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors [J].
Chollet, AM ;
Le Diguarher, T ;
Murray, L ;
Bertrand, M ;
Tucker, GC ;
Sabatini, M ;
Pierré, A ;
Atassi, G ;
Bonnet, J ;
Casara, P .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (03) :295-299
[6]   PHOTOLYSIS OF ALPHA-ARYLOXY-KETONES [J].
COLLIER, JR ;
DIRANIA, MKM ;
HILL, J .
JOURNAL OF THE CHEMICAL SOCIETY C-ORGANIC, 1970, (01) :155-&
[7]   Characterisation of human melatonin mt1 and MT2 receptors by CRE-luciferase reporter assay [J].
Conway, S ;
Canning, SJ ;
Howell, HE ;
Mowat, ES ;
Barrett, P ;
Drew, JE ;
Delagrange, P ;
Lesieur, D ;
Morgan, PJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 390 (1-2) :15-24
[8]   Melatonin, its receptors, and relationships with biological rhythm disorders [J].
Delagrange, P ;
GuardiolaLemaitre, B .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (06) :482-510
[9]   SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NOVEL NAPHTHALENIC AND BIOISOSTERIC RELATED AMIDIC DERIVATIVES AS MELATONIN RECEPTOR LIGANDS [J].
DEPREUX, P ;
LESIEUR, D ;
MANSOUR, HA ;
MORGAN, P ;
HOWELL, HE ;
RENARD, P ;
CAIGNARD, DH ;
PFEIFFER, B ;
DELAGRANGE, P ;
GUARDIOLA, B ;
YOUS, S ;
DEMARQUE, A ;
ADAM, G ;
ANDRIEUX, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (20) :3231-3239
[10]   REACTION OF PHENOLS WITH ALPHA-CHLORO-KETONES IN PRESENCE OF POTASSIUM IODIDE [J].
DIRANIA, MKM ;
HILL, J .
JOURNAL OF THE CHEMICAL SOCIETY C-ORGANIC, 1969, (16) :2144-&